Does The Match rank to fail?; the complicated connection between adoption and abortion; and more

March 12, 2023 Check out STAT+

Sponsored By

By Patrick Skerrett Editor, First Opinion

After seven-plus years, 3,307 essays published, 65 podcasts recorded, and 339 newsletters assembled, I am handing over First Opinion to Torie Bosch, who is primed to make it an even more vibrant platform for opinion and perspective essays on the life sciences. Please keep reading and sending ideas and essays to first.opinion@statnews.com.

Dom Smith/STAT Ranked to fail: Does gatekeeping affect diversity in The Match? The National Residency Matching Program needs to share demographic data on students who do not match into residency programs. By Onyekachi T. Otugo and Al'ai Alvarez and Adaira I. Landry STAT+ | Use warranties, not outcomes-based agreements, to make payers whole when a gene therapy fails Health care systems can't pay for multi-million-dollar single-dose gene therapy treatments that might not work. Warranties are one solution. By Emad Samad Adobe Clearing the patent thicket: A pathway to faster generic drug approvals The widespread use of patent thickets to delay generic competition results from a mistake by the FDA in interpreting the Hatch-Waxman Act. By Alfred Engelberg The PEPFAR legacy: Lessons for global health planning from 20 years of AIDS work PEPFAR, the President's Emergency Plan for AIDS Relief, which became law 20 years ago, has helped change the face of global health. By Peter Yeo Adobe How cross-state licensure reform can ease America's mental health crisis The antiquated system of licensure in the U.S. is creating a huge barrier to realizing the potential of telehealth for mental health care. By Harry Ritter Congress must fix the IRA's small molecule penalty A change wrought by the Inflation Reduction Act puts the development of small molecule drugs at a disadvantage compared to biologics. By John Stanford STAT+ | Developing new drugs starts with building the next generation of clinical investigators Improving equity in the development of new drugs starts with ensuring more equitable representation among clinical trial investigators. By Irfan Khan

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying First Opinion? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser